Sign In
Buy NTRA
$318.35
-3.75 (-1.16%)
At Close: Aug 10, 2026
Medical Stock Hovers Near Buy Point After 46% Gain
01:49pm, Tuesday, 30'th Dec 2025
Natera stock is near its all-time high after gaining 46% year to date.
Cwm LLC Increases Stake in Natera, Inc. $NTRA
04:07am, Monday, 29'th Dec 2025
Cwm LLC raised its stake in Natera, Inc. (NASDAQ: NTRA) by 72.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 70,925 s
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
08:00am, Monday, 22'nd Dec 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will participate in the 44th Annual J.P. Morgan Healthcare
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
08:00am, Thursday, 18'th Dec 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Quantum Leap Healthcare Collaborative, today announced the publicati
Castleark Management LLC Has $5.87 Million Stake in Natera, Inc. $NTRA
03:54am, Monday, 15'th Dec 2025
Castleark Management LLC lessened its position in Natera, Inc. (NASDAQ: NTRA) by 19.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Co
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
08:00am, Friday, 12'th Dec 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology rese
Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks
09:11am, Thursday, 11'th Dec 2025
Stanley Druckenmiller is a Wall Street legend whose trades are truly worth tracking due to how consistently he has been winning.
Baird Financial Group Inc. Has $4.50 Million Stock Holdings in Natera, Inc. $NTRA
05:46am, Thursday, 11'th Dec 2025
Baird Financial Group Inc. increased its holdings in shares of Natera, Inc. (NASDAQ: NTRA) by 277.8% during the undefined quarter, according to the company in its most recent 13F filing with the SEC.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Co
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
08:00am, Tuesday, 09'th Dec 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today shared the results from two oral presentations that were presented at the Am
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?
01:33pm, Friday, 05'th Dec 2025
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stock is trading lower on Friday, despite no company-specific news, likely reacting to Natera Inc.'s (NASDAQ: NTRA) acquisition of cancer diagnostic
Natera Acquires Foresight Diagnostics
07:00am, Friday, 05'th Dec 2025
AUSTIN, Texas & BOULDER, Colo.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular r
Edgestream Partners L.P. Grows Stock Position in Natera, Inc. $NTRA
04:38am, Thursday, 04'th Dec 2025
Edgestream Partners L.P. lifted its position in Natera, Inc. (NASDAQ: NTRA) by 154.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissio
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
08:00am, Wednesday, 03'rd Dec 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Societ
